Lilly Alimta To Be Available In Two Weeks Following Five-Month Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.
You may also be interested in...
Alimta Beats Gemcitabine In Some NSCLC Types
But Phase III results show similar efficacy in patients overall.
Alfacell Plans Subset Onconase NDA Despite Phase III Shortfall In Mesothelioma
Drug works in chemo failures; filing by year’s end, CFO tells “The Pink Sheet” DAILY.
Alimta Beats Gemcitabine In Some NSCLC Types
But Phase III results show similar efficacy in patients overall.